Why the study?
Haemopericardium has rarely been described in association with non-vitamin K antagonist oral anticoagulant use, with only two previous reports associated with dabigatran.
Idarucizumab can be effectively used as a reversal agent prior to emergent pericardiocentesis in patients with dabigatran-induced haemopericardium and cardiac tamponade.
May indicate idarucizumab utility in dabigatran tamponade; leaves open need for prospective data.
Haemopericardium has rarely been described in association with the use of a non-vitamin K antagonist oral anticoagulant. Cardiac tamponade is a life-threatening condition that usually requires urgent pericardiocentesis. Here, the authors report a case of haemopericardium with cardiac tamponade during dabigatran therapy for atrial fibrillation in a patient with chronic coronary syndrome, treated effectively with reversal agent idarucizimab before pericardiocentesis. To the authors’ knowledge, this is only the third report of dabigatran-induced haemopericardium.
No takes yet. Share an insight, caveat, or question.
Palmerini et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: